15.05.2013 18:05 Uhr, Quelle: Wallstreet online
Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA
Not Intended for US Media New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases Xofigo shown in a pivotal phase III trial to significantly improve overall survival Algeta to host international …
Weiterlesen bei Wallstreet online
JustMac.info